Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Up 4.3% Following Analyst Upgrade

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report)'s stock price traded up 4.3% during trading on Thursday after StockNews.com upgraded the stock from a sell rating to a hold rating. The stock traded as high as $126.94 and last traded at $124.66. 64,418 shares were traded during mid-day trading, a decline of 83% from the average session volume of 387,802 shares. The stock had previously closed at $119.50.

Several other equities analysts also recently commented on ASND. Jefferies Financial Group increased their price objective on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a "buy" rating in a research note on Tuesday, August 13th. Morgan Stanley raised their price target on shares of Ascendis Pharma A/S from $116.00 to $140.00 and gave the company an "equal weight" rating in a research report on Thursday, May 16th. Oppenheimer raised Ascendis Pharma A/S from a "market perform" rating to an "outperform" rating and set a $180.00 target price for the company in a research report on Thursday. The Goldman Sachs Group upped their price objective on shares of Ascendis Pharma A/S from $170.00 to $195.00 and gave the company a "buy" rating in a report on Tuesday, August 13th. Finally, Stifel Nicolaus initiated coverage on shares of Ascendis Pharma A/S in a report on Friday, May 31st. They issued a "buy" rating and a $200.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $187.08.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of large investors have recently modified their holdings of ASND. Vestal Point Capital LP purchased a new stake in shares of Ascendis Pharma A/S in the fourth quarter valued at approximately $78,719,000. GSA Capital Partners LLP bought a new stake in shares of Ascendis Pharma A/S in the 1st quarter worth about $992,000. Price T Rowe Associates Inc. MD raised its position in shares of Ascendis Pharma A/S by 23.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company's stock valued at $269,374,000 after acquiring an additional 336,976 shares in the last quarter. ADAR1 Capital Management LLC acquired a new stake in Ascendis Pharma A/S during the fourth quarter worth about $5,779,000. Finally, Perceptive Advisors LLC acquired a new stake in shares of Ascendis Pharma A/S during the 4th quarter worth approximately $16,648,000.

Ascendis Pharma A/S Trading Down 0.4 %

The stock has a market capitalization of $6.93 billion, a P/E ratio of -12.38 and a beta of 0.63. The company's 50-day moving average is $134.73 and its two-hundred day moving average is $138.46.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.